Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.

Abstract excerpt

Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in most cases. For more than 40 years, the standard up-front induction treatment has been a combination of continuous-infusion cytarabine and an anthracycline. Risk stratification by molecular and cytogenetic characteristics and measurable residual disease (MRD)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allografts
• Share to fms-Like Tyrosine Kinase 3
• Share to FLT3 gene